Molbio Diagnostics has entered the unicorn club with a valuation of $1.6 billion after raising $85 million from Temasek and existing investor Motilal Oswal Alternates. The funding will strengthen Molbio’s ability to develop and commercialize near-care diagnostic technologies and accelerate the global rollout of its flagship Truenat platform. Known for its portable, point-of-care molecular diagnostics, Truenat is deployed across 40 countries and endorsed by WHO for TB diagnosis. This strategic investment marks a major step in Molbio’s mission to make high-quality diagnostics accessible worldwide.
